Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
Milton, GB
Size (employees)
348 (est)+2%
Immunocore is headquartered in Milton, GB
Report incorrect company information

Key People/Management at Immunocore

Eliot Forster

Eliot Forster

Chief Executive Officer
Paul Fry

Paul Fry

Chief Financial Officer
Christina Coughlin

Christina Coughlin

Chief Medical Officer
Bent Jakobsen

Bent Jakobsen

Chief Scientific Officer
Eva-Lotta Allan

Eva-Lotta Allan

Chief Business Officer
James Sandy

James Sandy

Chief Development Officer
Andrew Hotchkiss

Andrew Hotchkiss

Chief Commercial Officer

Immunocore Office Locations

Immunocore has an office in Milton
Milton, GB (HQ)
101 Park Drive, Milton Park, Abingdon, Oxon
Milton, GB (HQ)
101 Park Dr
Show all (2)
Report incorrect company information

Immunocore Financials and Metrics

Summary Metrics

Total Funding

$320 m

Latest funding size

$320 m

Time since last funding

3 years ago


Immunocore's latest funding round in July 2015 was reported to be $320 m. In total, Immunocore has raised $320 m

Immunocore Financials

Immunocore's revenue was reported to be £16.47 m in FY, 2016

Revenue (FY, 2016)

16.5 m

Net income (FY, 2016)

(40.8 m)

EBITDA (FY, 2016)

(51.7 m)

EBIT (FY, 2016)

(54.4 m)

Cash (2-Mar-2018)

176.6 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016


2 m6.4 m14.3 m16.5 m

Revenue growth, %


Operating expense total

6.8 m13.7 m(2.9 m)70.9 m


(4.4 m)(7.3 m)18.9 m(51.7 m)
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(5.6 m)16.8 m(40.8 m)

Cash From Operating Activities

11.3 m40.3 m(22.4 m)(38 m)

Cash From Financing Activities

3 m404 k197.7 m96 k

Net Change in Cash

13.8 m34.5 m168.9 m(43.1 m)
GBPY, 2016


102 k

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information